Live attenuated varicella vaccine

Annual Review of Microbiology

Volumn 50, Issue , 1996, Pages 59-100

  Arvin, Ann M ^a   Gershon, Anne A ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

antiviral therapy; chicken pox; herpes zoster; immunization; latent virus infection; shingles

Indexed keywords

CHICKENPOX VACCINE;

CHICKENPOX; DRUG EFFICACY; DRUG SAFETY; HERPES ZOSTER; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS ATTENUATION;

ADULT; CANADA; CHICKENPOX; CHICKENPOX VACCINE; CHILD; HERPES ZOSTER; HUMANS; UNITED STATES; VACCINATION; VACCINES, ATTENUATED; VIRUS LATENCY;

GALLUS GALLUS; HERPES; HERPES ZOSTER; HUMAN HERPESVIRUS 3;

EID: 0029795659     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.50.1.59     Document Type: Review

References (262)

1. Alessi E, Cusini M, Zerboni R, Calvicchini S, Uberti-Foppa C, et al. 1988. Unusual varicella zoster virus infection in patients with the acquired immunodeficiency syndrome. Arch. Dermatol. 124:1011-13
2. Alter SJ, McVey CJ, Jenski L, Myers M. 1985. Varicella live virus vaccine in normal susceptible adults at high risk for exposure. Presented at Intersci. Conf. Antimicrob. Agents Chemother., Minneapolis, MN, Abstr. 457
3. Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahlingham R, Davis LE, Gilden DH. 1995. The vasculopathy of varicella-zoster virus encephalitis. Ann. Neurol. 37:784-90
4. Anderson DR, Schwartz J, Hunter NJ, Cottrill C, Bisaccia E, Klainer ES. 1994. Varicella hepatitis: a fatal case in a previously healthy immunocompetent adult. Report of a case, autopsy, and review of the literature. Arch. Int. Med. 154:2101-6
5. Arbeter AM, Granowetter L, Starr SE, Lange B, Wimmer R, Plotkin SA. 1990. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics 85:338-44
6. Arbeter AM, Starr SE, Plotkin SA. 1986. Varicella vaccine studies in healthy children and adults. Pediatrics 78:748-56 (Suppl.)
7. Aronson J, McSherry G, Hoyt L, Boland M, Oleske J, et al. 1992. Varicella in children with HIV infection. Pediatr. Infect. Dis. J. 11:1004-8
8. Arvin AM. 1992. Cell-mediated immunity to varicella-zoster virus. J. Infect. Dis. 166:S35-S41
9. Arvin AM. 1995. Varicella-zoster virus. In Virology, ed. B Fields, pp. 2547-86. New York: Raven. 3rd ed.
10. Arvin AM, Kinney-Thomas E, Shriver K, Grose C, Koropchak CM, et al. 1986. Immunity to varicella-zoster glycoproteins, gpI (gp 90/58) and gp III (gp 118), and to a nonglycosulated protein, p. 170. J. Immunol. 137:1346-51
11. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. 1986. Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J. Infect. Dis. 154:422-29
12. Arvin AM, Koropchak CM, Wittek AE. 1983. Immunological evidence of reinfection with varicella-zoster virus. J. Infect. Dis. 148:200-5
13. Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, et al. 1991. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J. Immunol. 146:257-64
14. Asano Y, Itakura N, Hiroishi Y, Hirose S, Nagai T, et al. 1985. Viremia is present in incubation period in nonimmunocompromised children with varicella. J. Pediatr. 106:69-71
15. Asano Y, Itakura N, Hiroishi Y, Hirose S, Ozaki T, et al. 1985. Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine. J. Infect. Dis. 152:863-68
16. Asano Y, Itakura N, Kajita Y, Suga S, Yoshikawa T, et al. 1990. Severity of viremia and clinical findings in children with varicella. J. Infect. Dis. 161:1095-98
17. Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S, et al. 1977. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 59:3-7
18. Asano Y, Suga S, Yoshikawa T, Kobayashi H, Yazaki T, et al. 1994. Experience and reason: twenty year follow up of protective immunity of the Oka live varicella vaccine. Pediatrics 94:524-26
19. Balfour HH. 1988. Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Am. J. Med. 85(2A):68-73 (Suppl.)
20. Balfour HH, Benson C, Braun J, Cassnes B, Erice A, et al. 1994. Management of acyclovir-resistant herpes simplex and varicella-zoster infections. J. Acquired Immune Defic. Syndr. 7:254-60
21. Balfour HH, Kelly JM, Suarez CS, Heussner RC, Englund JA, et al. 1990. Acyclovir treatment of varicella in otherwise healthy children. J. Pediatr. 116:633-39
22. Balfour HH, Rotbart H, Feldman S, Dunkle L, Feder H, et al. 1992. Acyclovir treatment of varicella in otherwise healthy adolescents. J. Pediatr. 120:627-33
23. Bennett GJ. 1994. Hypotheses on the pathogenesis of herpes zoster-associated pain. Ann. Neurol. 35(S):S38-S41
24. Bergen RE, Diaz PS, Arvin AM. 1990. The immunogenicity of Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J. Infect. Dis. 162:1049-54
25. Bergen RE, Sharp M, Sanchez A, Judd AK, Arvin A. 1991. Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE 62) and glycoprotein I of varicella-zoster virus. Viral Immunol. 4:151-66
26. Berger R, Luescher D, Just M. 1984. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J. Infect. Dis. 149:647
27. Beutner KR, Friedman DJ, Forszpaniak C, Anderson PL, Wood MJ. 1995. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother. 39:1546-53
28. Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron K, Balfour H. 1994. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J. Infect. Dis. 170:68-75
29. Broyer M, Boudailliez B. 1985. Varicella vaccine in children with chronic renal insufficiency. Postgrad. Med. J. 61(S4):103-6
30. Brunell P, Geiser C, Novelli V, Lipton S, Narkewicz S. 1987. Varicella-like illness caused by live varicella vaccine in children with acute lymphocytic leukemia. Pediatrics 79:922-27
31. Brunell PA. 1989. Transmission of chickenpox in a school setting prior to the observed exanthem. Am. J. Dis. Child. 143:1451-52
32. Brunell PA, Novelli VM, Lipton SV, Pollock B. 1988. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics 81:779-84
33. Brunell PA, Shehab Z, Geiser C, Waugh JE. 1982. Administration of live varicella vaccine to children with leukemia. Lancet 2:1069-73
34. Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E. 1986. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 77:53-56
35. Buchbinder SP, Katz MH, Hessol N, Liu J, O'Malley P, et al. 1992. Herpes zoster and human immunodeficiency virus infection. J. Infect. Dis. 166:1153-56
36. Chartrand S, Madison BG, Steinberg S, Gershon A. 1985. Varicella vaccine in day care centers. Presented at Intersci. Conf. Antimicrob. Agents Chemother., Minneapolis, MN. Abstr. 454
37. Clarke P, Beer T, Gilden DH. 1995. Configuration and terminal sequences of the simian varicella virus. Virology 207:154-59
38. Clements DA, Armstrong CB, Ursano AM, Moggio M, Walter EB, Wilfert CM. 1995. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr. Infect. Dis. J. 14:874-79
39. Cohen J, Seidel KE. 1994. Varicella-zoster virus (VZV) open reading frame (ORF) 10 protein the homologue of the essential herpes simplex virus protein VP16, is dispensible for VZV replication in vitro. J. Virol. 68:7850-58
40. Cohen J, Straus SE. 1995. Varicella-zoster virus and its replication. In Virology, ed. B Fields, pp. 2525-46. New York: Raven. 3rd ed.
41. Cohen JI, Seidel KE. 1993. Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. Proc. Natl. Acad. Sci. USA 90:7376-80
42. Cohen JI, Seidel KE. 1994. Absence of varicella zoster virus (VZV) glycoprotein V (gp V) does not alter growth of VZV in vitro or sensitivity to heparin. J. Gen. Virol. 75:3087-93
43. Cohen JI, Seidel KE. 1995. Varicella zoster virus (VZV) open reading frame (ORF) 1 encodes a membrane protein that is dispensible for growth of VZV in vitro. Virology 206:835-42
44. Cohen PR, Grossman ME. 1989. Clinical features of human immunodeficiency virus-associated disseminated herpes zoster virus infection - a review of the literature. Clin. Exp. Dermatol. 14:273-76
45. Connelly BL, Stanberry LR, Bernstein DI. 1993. Detection of varicella-zoster virus DNA in nasopharyngeal secretions of immune household contacts of varicella. J. Infect. Dis. 168:1253-55
46. Cook ML, Stevens J. 1968. Labile coat: reason for noninfectious cell-free varicella zoster virus in culture. J. Virol. 2:1458-64
47. Croen KD, Ostrove JM, Dragovic LY, Straus SE. 1988. Patterns of gene expression and sites of latency in human ganglia are different for varicella-zoster and herpes simplex viruses. Proc. Natl. Acad. Sci. USA 85:9773-77
48. Cuthbertson G, Grose C. 1988. Biotinylated and radioactive DNA probes for detection of varicella-zoster virus genome in infected human cells. Mol. Cell. Probes 2:197-207
49. Davison AJ, Edson CM, Ellis RW, Forghani B, Gilden D, et al. 1986, New common nomenclature for glycoprotein genes of varicella-zoster virus and their products. J. Virol. 57:1195-97
50. Davison AJ, Scott JE. 1986. The complete DNA sequence of varicella-zoster virus. J. Gen. Virol. 67:1759-816
51. Debrus S, Sadzot-Delvaux C, Nikkels AF, Piette J, Rentier B. 1995. Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency. J. Virol. 69:3240-45
52. Devlin ME, Gilden DH, Mahlingham R, Dueland AN, Cohrs R. 1992. Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA. J. Infect. Dis. 165:619-22
53. Diaz PS, Au D, Smith S, Amylon M, Link M, et al. 1991. Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 87:166-70
54. Dolin R, Reichman RC, Mazur MH, Whitley RJ. 1978. Herpes-zoster varicella infections in immunosuppressed patients. Ann. Intern. Med. 89:375-88
55. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM, et al. 1991. A controlled trial of oral acyclovir for chickenpox in normal-children. N. Engl. J. Med. 325:1539-44
56. Dworsky M, Whitley R, Alford C. 1980. Herpes zoster in early infancy. Am. J. Dis. Child. 134:618-19
57. Edwards TS. 1989. Ophthalmic complications from varicella. J. Pediatr. Oph-thalmol. 965:37-44
58. Elliott KJ. 1994. Other neurologic complications of herpes zoster and their management. Ann. Neurol. 35:S57-S61
59. Englund JA, Arvin AM, Balfour HH. 1990. Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal-children. J. Clin. Microbiol. 28:2327-30
60. Englund JA, Suarez CS, Kelly J, Tate D, Balfour H. 1989. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J. Pediatr. 114:37-44
61. Feldhoff C, Balfour H, Simmons SR, Najarian J, Mauer M. 1981. Varicella in children with renal transplants. J. Pediatr. 98:25-31
62. Feldman S, Hughes W, Daniel C. 1975. Varicella in children with cancer: 77 cases. Pediatrics 80:388-97
63. Feldman S, Hughes WT, Kim HY. 1973. Herpes zoster in children with cancer. Am. J. Dis. Child. 126:178-84
64. Feldman S, Lott L. 1987. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 80:465-72
65. Feldman SR, Ford MJ, Briggman RA. 1988. Herpes zoster and facial palsy. Cutis 42:523-24
66. Feusner JH, Slichter SJ, Harker LA. 1979. Mechanisms of thrombocytopenia in varicella. Am. J. Hematol. 7:255-62
67. Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S. 1981. Life-threatening complications of varicella. Am. J. Dis. Child. 135:896-99
68. Forghani B, Dupuis KW, Schmidt N. 1984. Varicella-zoster viral glycoproteins analyzed with monoclonal antibodies. J. Virol. 52:55-62
69. Forghani B, Grose C. 1994. Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex. Virology 199:458-62
70. Forghani B, Yu G, Hurst J. 1991. Comparison of biotinylated DNA and RNA probes for rapid detection of varicella-zoster virus genome by in situ hybridization. J. Clin. Microbiol. 29:583-91
71. Friedman CA, Temple DM, Robbins KK, Rawson JE, Wilson JP, Feldman S. 1994. Outbreak and control of varicella in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 13:152-54
72. Furuta Y, Takasu T, Fukuda S, Sato-Matsumura C, Inuyama Y, et al. 1992. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J. Infect. Dis. 166:1157-59
73. Gabel C, Dubey L, Steinberg S, Gershon M, Gershon A. 1989. Varicella-zoster virus glycoproteins are phosphorylated during posttranslational maturation. J. Virol. 63:4264-76
74. Gershon A. 1984. Immunoprophylaxis of varicella-zoster infections. Am. J. Med. 76:672-77
75. Gershon A. 1994. Chickenpox, Measles, and Mumps, pp. 565-618. Philadelphia: Saunders
76. Gershon A. 1995. Varicella-zoster virus: prospects for control. Adv. Pediatr. Infect. Dis. 10:93-124
77. Gershon A, Brunell P, Doyle EF, Claps A. 1972. Steroid therapy and varicella. J. Pediatr. 81:1034
78. Gershon A, Forghani B. 1995. Varicella-zoster virus. In Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections, ed. E Lennette, pp. 601-13. Washington, DC: Am. Public Health Assoc. 7th ed.
79. Gershon A, LaRussa P, Steinberg S. 1996. Varicella vaccine: use in immunocompromised patients. In Infectious Disease Clinics of North America, ed. CJ White, RE Ellis. Philadelphia: Saunders. In press
80. Gershon A, LaRussa P, Steinberg S, Lo SH, Mervish N, Meier P. 1996. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated aganst chickenpox. J. Infect. Dis. 173:450-53
81. Gershon A, Silverstein S. 1995. Clinical virology. In Varicella-Zoster Virus, ed. D Richman, F Hayden, R Whitley. New York: Churchill Livingstone. In press
82. Gershon A, Steinberg S, Borkowsky W, Lennette D, Lennette E. 1982. IgM to varicella-zoster virus: demonstration in patients with and without clinical zoster. Pediatr. Infect. Dis. 1:164-67
83. Gershon A, Steinberg S, Brunell P. 1974. Zoster immune globulin: a further assessment. N. Engl. J. Med. 290:243-45
84. Gershon A, Steinberg S, Gelb L, NIAID Collaborative Varicella Vaccine Study Group. 1986. Live attenuated varicella vaccine: use in immunocompromised children and adults. Pediatrics 78(S):757-62
85. Gershon A, Zhu Z, Sherman DL, Gabel CA, Ambron RT, Gershon MD. 1994. Intracellular transport of newly synthesized varicella-zoster virus: final envelopment in the trans-Golgi network. J. Virol. 68:6372-90
86. Gershon AA, LaRussa P, Steinberg S. 1991. Live attenuated varicella vaccine: current status and future uses. Semin. Pediatr. Infect. Dis. 2:171-78
87. Gershon AA, Steinberg S, Gelb L, NIAID Collaborative Varicella Vaccine Study Group. 1984. Clinical reinfection with varicella-zoster virus. J. Infect. Dis. 149:137-42
88. Gershon AA, Steinberg S, Gelb L, NIAID Collaborative Varicella Vaccine Study Group. 1984. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. J. Am. Med. Assoc. 252:355-62
89. Gershon AA, Steinberg S, LaRussa P, Hammerschlag M, Ferrara A, NIAID Collaborative Varicella Vaccine Study Group. 1988. Immunization of healthy adults with live attenuated varicella vaccine. J. Infect. Dis. 158:132-37
90. Gershon AA, Steinberg S, NIAID Collaborative Varicella Vaccine Study Group. 1989. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N. Engl. J. Med. 320:892-97
91. Gershon AA, Steinberg S, NIAID Collaborative Varicella Vaccine Study Group. 1990. Live attenuated varicella vaccine: protection in healthy adults in comparison to leukemic children. J. Infect. Dis. 161:661-66
92. Ghatak N, Zimmerman H. 1973. Spinal ganglion in herpes zoster. Arch. Pathol. 95:411-15
93. Gilden DH, Beinlich BR, Rubinstein EM, Stommel E, Swenson R, et al. 1994. Varicella-zoster virus myelitis: an expanding spectrum. Neurology 44:1818-23
94. Gilden DH, Wright R, Schneck S, Gwaltney JM, Mahalingam R. 1994. Zoster sine herpete, a clinical variant. Ann. Neurol. 35:530-33
95. Giller RH, Winistorfer S, Grose C. 1989. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J. Infect. Dis. 160:919-28
96. Gleaves C, Lee C, Bustamante C, Meyers J. 1988. Use of murine monoclonal antibodies for laboratory diagnosis of varicella-zoster virus infection. J. Clin. Microbiol. 26:1623-25
97. Gogos CA, Bassaris HP, Vagenakis AG. 1992. Varicella pneumonia in adults. A review of pulmonary manifestations, risk factors, and treatment. Respiration 59:339-43
98. Gold E. 1966. Serologic and virus-isolation studies of patients with varicella or herpes zoster infection. N. Engl. J. Med. 274:181-85
99. Gray WL, Pumphrey CY, Ruyechan WT, Fletcher TM. 1992. The simian varicella virus and varicella zoster virus genomes are similar in size and structure. Virology 186:562-72
100. Grose C. 1991. Glycoproteins of varicella-zoster virus and their herpes simplex virus homologs. Rev. Infect. Dis. 13:5960-63
101. Grose C, Ng T. 1992. Intracellular synthesis of varicella-zoster virus. J. Infect. Dis. 166:S7-S12(Suppl.)
102. Deleted in proof
103. Grose CH. 1981. Variation on a theme by Fenner. Pediatrics 68:735-37
104. Grossman MC, Grossman ME. 1993. Chronic hyperkeratotic herpes zoster and human immunodeficiency virus infection. J. Am. Acad. Dermatol. 28:306-8
105. Guess HA, Broughton DD, Melton LJ, Kurland LT. 1985. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 76:512-17
106. Guess HA, Broughton DD, Melton LJ, Kurland LT. 1987. Population-based studies of varicella complications. Pediatrics 78:723-27
107. Gustafson TL, Shehab Z, Brunell P. 1984. Outbreak of varicella in a newborn intensive care nursery. Am. Dis. Child. 138:548-50
108. Ha K, Baba K, Ikeda T, Nishida M, Yabuuchi H, Takahashi M. 1980. Application of a live varicella vaccine in children with acute leukemia or other malignancies without suspension of anticancer therapy. Pediatrics 65:346-50
109. Haake D, Zakowski PC, Haake DL, Bryson YJ. 1990. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev. Infect. Dis. 12:788-98
110. Hammerschlag MR, Gershon A, Steinberg S, Clarke L, Gelb L. 1989. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J. Infect. Dis. 160:535-37
111. Han CS, Miller W, Haake R, Weisdorf D. 1994. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transpl. 13:277-83
112. Hardy IB, Gershon A, Steinberg S, LaRussa P, NIAID Collaborative Study Group. 1991. Incidence of zoster after live attenuated varicella vaccine. Presented at Int. Conf. Antimicrob. Agents Chemother., Chicago, IL
113. Hardy IB, Gershon A, Steinberg S, LaRussa P, NIAID Collaborative Study Group. 1991. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N. Engl. J. Med. 325:1545-50
114. Hayakawa Y, Torigoe S, Shiraki K, Yamanishi K, Takahashi M. 1984. Biologic and biophysical markers of a live varicella vaccine strain (Oka): identification of clinical isolates from vaccine recipients. J. Infect. Dis. 149:956-63
115. Hayakawa Y, Yamamoto T, Yamanishi K, Takahashi M. 1986. Analysis of varicella zoster virus (VZV) DNAs of clinical isolates by endonuclease HpaI. J. Gen. Virol. 67:1817-29
116. Hayward A. 1990. T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J. Virol. 64:651-55
117. Hayward A, Herberger M. 1987. Lymphocyte responses to varicella-zoster virus in the elderly. J. Clin. Immunol. 7:174-78
118. Heineman TC, Cohen JI. 1994. Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro. J. Virol. 68:3317-23
119. Hellinger WC, Bolling JP, Smith TF, Campbell RJ. 1993. Varicella-zoster virus retinitis in a patient with AIDS-related complex: a case report and brief review of the acute retinal necrosis syndrome. Clin. Infect. Dis. 16:208-12
120. Hickling JK, Borysiewicz L, Sission P. 1987. Varicella-zoster virus-specific cytotoxic T lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood. J. Virol. 61:3463-69
121. Hilt DC, Buchholz D, Krumholz A, Weiss H, Wolinsky JS. 1983. Herpes zoster ophlthalmicus and delayed control ateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann. Neurol. 14:543-53
122. Hope-Simpson RE. 1965. The nature of herpes zoster: a long term study and a new hypothesis. Proc. R. Soc. Med. 58:9-20
123. Huang Y-C, Lin T-Y, Chiu C-H. 1995. Acyclovir prophylaxis of varicella after household exposure. Pediatr. Infect. Dis. J. 14:152-54
124. Huff JC, Bean B, Balfour HH, Laskin OL, Connor JD, et al. 1988. Therapy of herpes zoster with oral acyclovir. Am. J. Med. 85(2A):84-89 (Suppl.)
125. Huff JC, Drucker JL, Clemmer A, Laskin OL, Connor JD, et al. 1993. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J. Med. Virol. S1:93-96 (Suppl.)
126. Hughes P, LaRussa PS, Pearce JM, Lepow ML, Steinberg SP, Gershon A. 1994. Transmission of varicella-zoster virus from a vaccinee with underlying leukemia, demonstrated by polymerase chain reaction. J. Pediatr. 124:932-35
127. Hurley J, Greenslade T, Lewy P, Ahmadian Y, Firlit C. 1980. Varicella zoster infections in pediatric renal transplant patients. Arch. Surg. 115:751-52
128. Hurwitz ES, Goodman RA. 1982. A cluster of cases of Reye syndrome associated with chickenpox. Pediatrics 70:901-6
129. Huse DM, Meissner C, Lacey MJ, Oster G. 1994. Childhood vaccination against chickenpox: an analysis of benefits and costs. J. Pediatr. 124:869-74
130. Ihara T, Kamiya H, Starr SE, Arbeter A, Lange B. 1989. Natural killing of varicella-zoster virus (VZV)-infected fibroblasts in normal children, children with VZV infections, and children with Hodgkin's disease. Acta Pediatr. Jpn. 31:523-28
131. Izawa T, Ihara T, Hattori A, Iwasa T, Kamiya H, et al. 1977. Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics 60:805-9
132. Jackson MA, Burry VF, Olson L. 1992. Complications of varicella requiring hospitalization in previously healthy children. Pediatr. Infect. Dis. J. 11:441-45
133. Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, et al. 1990. Acyclovir-resistant varicella-zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 112:187-91
134. Jemsek J, Greenberg SB, Taber L, Harvey D, Gershon A, Couch R. 1983. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine 62:81-97
135. Johnson R, Milbourn PE. 1970. Central nervous system manifestations of chickenpox. Can. Med. Assoc. J. 102:831
136. Junker AK, Angus E, Thomas E. 1991. Recurrent varicella-zoster virus infections in apparently immunocompetent children. Pediatr. Infect. Dis. J. 10:569-75
137. Jura E, Chadwick E, Josephs SH, Steinberg S, Yogev R, et al. 1989. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr. Infect. Dis. J. 8:586-90
138. Karbassi M, Raizman MB, Schuman JS. 1992. Herpes zoster ophthalmicus. Surv. Ophthalmol. 36:395-410
139. Keller PM, Neff B, Ellis RW. 1984. Three major glycoprotein genes of varicella-zoster virus whose products have neutralization epitopes. J. Virol. 52:293-97
140. Kelley R, Mancao M, Lee F, Sawyer M, Nahmias A, Nesheim S. 1994. Varicella in children with perinatally acquired human immunodeficiency virus infection. J. Pediatr. 124:271-73
141. Kennedy PG, Major EO, Williams RK, Straus SE. 1994. Down-regulation of glial fibrillary acidic protein expression during acute lytic varicella-zoster virus infection of cultured human astrocytes. Virology 205:558-62
142. Kinchington PR, Ling P, Pensiero M, Moss B, Ruyechan WT, Hay J. 1990. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). J. Virol. 64:540-48
143. Kinchington PR, Vergnes JP, Defechereux P, Piette J, Turse SE. 1994. Transcriptional mapping of the varicella-zoster virus regulatory genes encoding open reading frames 4 and 63. J. Virol. 68:3570-81
144. Konno T, Yamaguchi Y, Minegishi M, Goto Y, Tsuchiyama S. 1984. A clinical trial of live attenuated varicella vaccine (Biken) in children with malignant diseases. Biken J. 27:115-18
145. Koropchak CM, Graham G, Palmer J, Winsberg M, Ting SF, et al. 1991. Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J. Infect. Dis. 163:1016-22
146. Koropchak CM, Solem SM, Diaz PS, Arvin AM. 1989. Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J. Virol. 63:2392-95
147. Kost RG, Kupinsky H, Straus SE. 1995. Varicella-zoster virus gene 63: transcript mapping and regulatory activity. Virology 209:218-24
148. Krause P, Klinman DM. 1995. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J. Pediatr. 127:518-25
149. Krugman S, Goodrich CH, Ward R. 1957. Primary varicella pneumonia. N. Engl. J. Med. 257:843-47
150. Kundratitz K. 1925. Experimentelle Ubertragung von Herpes Zoster auf den Mensschen und die Beziehungen von Herpes Zoster zu Varicellen. Monatsschr. Kinderheilk 29:516-23 (In German)
151. Kuppermann BD, Quiceno JI, Wiley C, Hesselink J, Hamilton R, et al. 1994. Clinical and histopathological study of varicella-zoster virus retinitis in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 118:589-600
152. Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, et al. 1995. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax R) in healthy adolescents and adults. Vaccine 13:967-72
153. Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, et al. 1991. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9:643-47
154. Kyong CU, Smith CD, Otherson HB. 1985. Necrotizing fascitis of the abdominal wall as a complication of chickenpox. Pediatr. Infect. Dis. J. 4:420-23
155. LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg S, Silverstein S. 1992. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J. Virol. 66:1016-20
156. Lawrence R, Gershon A, Holzman R, Steinberg S, NIAID Varicella Vaccine Collaborative Study Group. 1988. The risk of zoster after varicella vaccination in children with leukemia. N. Engl. J. Med. 318:543-48
157. Leboit PE, Limova M, Yen TS, Palefsky JM, White CR, Berger TG. 1992. Chronic verrucous varicella-zoster virus infection in patients with the acquired immunodeficiency syndrome (AIDS). Histologic and molecular biologic findings. Am. J. Dermatolopathol. 14:1-7
158. Leclair JM, Zaia J, Levin MJ, Congdon RG, Goldmann D. 1980. Airborne transmission of chickenpox in a hospital. N. Engl. J. Med. 302:450-53
159. Leibovitz E, Kaul A, Rigaud M, Bebenroth D, Krasinski K, Borkowsky W. 1992. Chronic varicella in a child infected with human immunodeficiency virus: case report and revew of the literature. Cutis 49:27-31
160. Lever WF, Schaumberg-Lever G. 1990. Histopathology of the Skin, pp. 404-6. Philadelphia: Lippincott
161. Levin M, Murray M, Rotbart H, Zerbe G, White CJ, Hayward AR. 1992. Immune response of elderly individuals to a live attenuated varicella vaccine. J. Infect. Dis. 166:253-59
162. Levin M, Murray M, Zerbe G, White CJ, Hayward AR. 1994. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J. Infect. Dis. 170:522-26
163. Liesegang TJ. 1991. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology 98:1216-29
164. Lieu T, Cochi S, Black S, Halloran ME, Shinefield HR, et al. 1994. Cost-effectiveness of a routine varicella vaccination program for U.S. children. J. Am. Med. Assoc. 271:375-81
165. Litwin V, Jackson W, Grose C. 1992. Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J. Virol. 66:3643-51
166. Liu GT, Urion DK. 1992. Pre-eruptive varicella encephalitis and cerebellar ataxia. Pediatr. Neurol. 8:69-70
167. Ljungman P, Lonnqvist B, Ringden O, Skinhoj P, Gahrton G. 1989. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transpl. 4:613-15
168. Locksley RM, Flournoy N, Sullivan KM, Meyers J. 1985. Infection with varicella-zoster virus after marrow transplantation. J. Infect. Dis. 152:1172-81
169. Lungu O, Annunziato P, Gershon A, Stegatis S, Josefson D, et al. 1995. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc. Natl. Acad. Sci. USA 92:10980-84
170. Lydick E, Kuter BJ, Zajac B, Guess H, NIAID Collaborative Varicella Vaccine Study Group. 1989. Association of steroid therapy with vaccine-associated rashes in children with acute lymphocytic leukaemia who received Oka/Merck varicella vaccine. Vaccine 7:549-53
171. Lynfield R, Herrin JT, Rubin RH. 1992. Varicella in pediatric renal transplant patients. Pediatrics 90:216-20
172. Martin JH, Dohner D, Wellinghoff WJ, Gelb LD. 1982. Restriction endonuclease analysis of varicella-zoster vaccine virus and wild type DNAs. J. Med. Virol. 9:69-76
173. McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC. 1989. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 83:256-61
174. McKendrick M, McGill J, White J, Woos M. 1986. Oral acyclovir in acute herpes zoster. Br. Med. J. 293:1529-32
175. Meier JL, Straus SE. 1992. Comparative biology of latent varicella-zoster virus and herpes simplex virus infections. J. Infect. Dis. 166(S1):S13-S23
176. Meyers JD, Flurnoy N, Thomas ED. 1980. Cell-mediated immunity to varicella-zoster virus after allogeneic bone marrow transplantation. J. Infect. Dis. 141:479-87
177. Miller E, Cradock-Watson JE, Ridehalgh MKS. 1989. Outcome in newborn babies given anti-varicella immunoglobulin after perinatal infection with varicella-zoster virus. Lancet 2:371-73
178. Moffat JF, Stein MD, Kaneshima H, Arvin AM. 1995. Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J. Virol. 69:5236-42
179. Moriuchi H, Moriuchi M, Cohen JI. 1994. The RING finger domain of the varicella-zoster virus open reading frame 61 protein is required for its transregulatory functions. Virology 205:238-46
180. Moriuchi H, Moriuchi M, Dean H, Cheung AK, Cohen JI. 1995. Pseudorabies virus EPO is functionally homologous to varicella-zoster virus ORF61 protein and herpes simplex virus type I. Virology 209:281-83
181. Myers MG. 1979. Viremia caused by varicella-zoster virus: association with malignant progressive varicella. J. Infect. Dis. 140:229-33
182. Myers MG, Connelly B, Stanberry LR. 1991. Varicella in hairless guinea pigs. J. Infect. Dis. 163:746-51
183. Nader S, Bergen R, Sharp M, Arvin A. 1995. Comparison of cell-mediated immunity (CMI) to varicella-zoster virus (VZV) in children and adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 171:13-17
184. Nunoue T. 1984. Clinical observations on varicella-zoster virus vaccinees treated with immunosuppressants for a malignancy. Biken J. 27:115-18
185. Ooi PL, Goh KT, Doraisingham S, Ling AE. 1992. Prevalence of varicella-zoster virus infection in Singapore. S. E. Asian J. Trop. Med. Public Health 23:22-25
186. Ozaki T, Ichikawa T, Matsui Y, Kondo T, Nagai T, et al. 1986. Lymphocyte-associated viremia in varicella. J. Med. Virol. 19:249-53
187. Ozaki T, Kajita Y, Asano Y, Aono K, Yamanishi K. 1994. Detection of varicella-zoster virus DNA in blood of children with varicella. J. Med. Virol. 44:263-65
188. Ozaki T, Matsuda Y, Asano Y, Kondo K, Namazue J, Yamanishi K. 1994. Investigation of varicella-zoster virus DNA by the polymerase chain reaction in healthy children with varicella vaccination. J. Med. Virol. 42:47-51
189. Ozaki T, Matsui Y, Asano Y, Okuno T, Yamanishi K, Takahashi M. 1989. Study of virus isolation from pharyngeal swabs in children with varicella. Am. J. Dis. Child. 143:1448-50
190. Ozaki T, Miwata H, Asano Y, Namazue J, Yamanishi Y. 1993. Varicella-zoster virus DNA in throat swabs of vaccinees. Arch. Dis. Child. 267:328-29
191. Paryani SG, Arvin AM. 1986. Intrauterine infection with varicella-zoster virus after maternal varicella. N. Engl. J. Med. 314:1542-46
192. Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, et al. 1994. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N. Engl. J. Med. 330:901-5
193. Patterson LER, Butler KM, Edwards MS. 1989. Clinical herpes zoster shortly following primary varicella in two HIV-infected children. Clin. Pediatr. 28:354
194. Peck RW, Weatherley BC, Wootton R, Crome P, Holditch TA, Posner J. 1995. Pharmacokinetics and tolerability of single doses of 882C87, a potent new anti-varicella-zoster virus agent, in healthy volunteers. Antimicrob. Agents Chemother. 39:20-27
195. Perera LP, Kaushal S, Kinchington PR, Mosca JD, Hayward GS, Straus SE.
196. Perera LP, Mosca JD, Ruyechan WT, Hay J. 1992. Regulation of varicella-zoster virus gene expression in human T lymphocytes. J. Virol. 66:5298-304
197. Perren T, Powles R, Easton D, Stolle K, Selby P. 1988. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am. J. Med. 85(2A):99-101 (Suppl.)
198. Peters ACB, Versteeg J, Lindeman J, Bots GTAM. 1978. Varicella and acute cerebellar ataxia. Arch. Neurol. 35:769-71
199. Plotkin SA, Starr S, Connor K, Morton D. 1989. Zoster in normal children after varicella vaccine. J. Infect. Dis. 159:1000-1
200. Portenoy RK, Duma C, Foley KM. 1986. Acute herpetic and post-herpetic neuralgia: clinical review and current management. Ann. Neurol. 20:651-64
201. Poscher ME. 1994. Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDS: report of four cases and review. AIDS 8:1115-17
202. Preblud S, Bregman DJ, Vernon LL. 1985. Deaths from varicella in infants. Pediatr. Infect. Dis. 4:503-7
203. Preblud S, Orenstein W, Bart K. 1984. Varicella: clinical manifestations, epidemiology, and health impact on children. Pediatr. Infect. Dis. 3:505-9
204. Preblud SR. 1981. Age-specific risks of varicella complications. Pediatrics 68:14-17
205. Preblud SR. 1986. Varicella: complications and costs. Pediatrics 76:728-35 (Suppl.)
206. Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR. 1985. A benefit-cost analysis of a childhood vaccination programme. Postgrad. Med. J. 61:17-22
207. Prober C, Kirk LE, Keeney RE. 1982. Acyclovir therapy of chickenpox in immunocompromised children - a collaborative study. J. Pediatr. 101:622-25
208. Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry HO. 1982. Risk of cancer after herpes zoster. N. Engl. J. Med. 307:393-97
209. Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry HO. 1982. Population-based study of herpes zoster and its sequelae. Medicine 61:310-16
210. Reichman RC. 1978. Neurologic complications of varicella-zoster infections. Ann. Intern. Med. 375:89-96
211. Rodriquez JE, Monninger T, Grose C. 1993. Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology 196:840-44
212. Ross AH, Lencher E, Reitman G. 1962. Modification of chickenpox in family contacts by administration of gamma globulin. N. Engl. J. Med. 267:369-76
213. Sadzot-Delvaux C, Merville-Louis M-P, Delree P, Marc P, Moonen G, Rentier B. 1990. An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J. Neurosci. Res. 26:83-89
214. Safrin S, Berger T, Gilson I, Wolfe P, Wofsy C, et al. 1991. Foscarnet therapy in five patients with AIDS andacyclovir-resistant varicella-zoster infection. Ann. Intern. Med. 115:19-21
215. Saltzman R, Boon R. 1995. The safety of famciclovir in patients with herpes zoster. Curr. Ther. Res. 56:219-25
216. Sato Y, Miyano T, Kawauchi K, Yokoyama M. 1984. Use of live varicella vaccine in acute leukemia and malignant lymphoma. Biken J. 27:111-13
217. Sawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR. 1993. Detection of varicella-zoster virus DNA in air samples from hospital rooms. J. Infect. Dis. 169:91-94
218. Sawyer MH, Wu YN, Chamberlin CJ, Burgos C, Brodine SK, et al. 1992. Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella. J. Infect. Dis. 166:885-88
219. Schmader K, George LK, Burchett GM, Pieper CF, Hamilton JD. 1995. Racial differences in the occurrencee of herpes zoster. J. Infect. Dis. 171:701-4
220. Schmidbauer M, Budka H, Pilz P, Kurata T, Hondo R. 1992. Presence, distribution and spread of productive varicella zoster virus infection in nervous tissues. Brain 115:383-98
221. Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. 1989. Herpes zoster infection after autologous bone marrow transplantation. Blood 74:1424-27
222. Sharp M, Terada K, Wilson A, Nader S, Kinchington P, et al. 1992. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 165:852-58
223. Spector T, Harrington JA, Morrison RW, Lambe CU, Nelson DJ, et al. 1989. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Proc. Natl. Acad. Sci. USA 86:1051-55
224. Srugo I, Courville T, Israele V, Wittek A, Brunell P. 1991. Varicella-zoster virus infection in HIV-1 infected children. Presented at Soc. Pediatr. Res., New Orleans
225. Starr S. 1992. Varicella in children receiving steroids for asthma: risks and management. Pediatr. Infect. Dis. J. 11:419-20
226. Stevenson D, Colman KL, Davison AJ. 1994. Characterization of the putative protein kinases specified by the varicella-zoster virus genes 47 and 66. J. Gen. Virol. 75:317-26
227. Deleted in proof
228. Straus SE, Hay J, Smith H, Owens J. 1983. Genome differences among varicella-zoster isolates. J. Gen. Virol. 64:1031-41
229. Straus SE, Ostrove JM, Inchauspe G, Felser JM, Freifeld A, et al. 1988. Varicella-zoster virus infections: biology, natural history, treatment, and prevention. Ann. Intern. Med. 108:221-37
230. Tadaka M, Suzutani T, Yoshida I, Matoba M, Azuma M. 1995. Identification of varicella-zoster virus strains by PCR analysis of three repeat elements and a PstI-site-less region. J. Clin. Virol. 33:658-60
231. Takahashi M. 1986. Clinical overview of varicella vaccine: development and early studies. Pediatrics 78:736-41
232. Takahashi M, Gershon A. 1994. Varicella vaccine. In Vaccines, ed. E Mortimer, S Plotkin, pp. 387-417. Philadelphia: Saunders. 2nd ed.
233. Takahashi M, Gershon A. 1996. Live attenuated varicella vaccine. In Vaccines, ed. M Levine. In press
234. Takahashi M, Kamiya H, Baba K, Asano Y, Ozaki T, Horiuchi K. 1985. Clinical experience with Oka live varicella vaccine in Japan. Postgrad. Med. 61:61-67
235. Takahashi M, Okuno Y, Otsuka T, Ozame J, Takamizawa A, et al. 1975. Development of a live attenuated varicella vaccine. Biken J. 18:25-33
236. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. 1974. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288-90
237. Takayama M, Takayama N, Kameoka Y, Hachimori K, Kaneda K, Minamitani M. 1989. Comparative restriction endonuclease analysis of varicella-zoster virus clinical isolates. Med. Microbiol. Immunol. 178:61-67
238. Tanaka K, Tsuda S, Sasai Y. 1994. Scanning and transmission electron microscopic studies of lesional epidermis in herpes zoster. J. Dermatol. 21:560-70
239. Tsolia M, Gershon A, Steinberg S, Gelb L. 1990. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J. Pediatr. 116:184-89
240. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, et al. 1995. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and post herpetic neuralgia. Ann. Intern. Med. 123:89-96
241. Vafai A, Murray R, Wellish W, Devlin M, Gilden D. 1988. Expression of varicella-zoster virus and herpes simplex virus in normal human trigeminal ganglia. Proc. Natl. Acad. Sci. USA 85:2362-66
242. von Bokay J. 1909. Uber den aetiologischen Zusammenhang der Varizellen mit gewissen Fallen von Herpes Zoster. Wien Klin. Wochenschr. 22:1323-26 (In German)
243. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC. 1992. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann. Intern. Med. 117:358-63
244. Deleted in proof
245. Wallace MR, Woelfl I, Bowler WA, Olson PE, Murray NB, et al. 1994. Tumor necrosis factor, interleukin-2, and interferon-gamma in adult varicella. J. Med. Virol. 43:69-71
246. Watson B, Boardman C, Laufer D, Piercy S, Tustin N, et al. 1995. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin. Infect. Dis. 20:316-19
247. Watson B, Gupta R, Randall T, Starr S. 1993. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J. Infect. Dis. 169:197-99
248. Watson B, Piercy S, Soppas D, Browngoehl K, Warner M, et al. 1993. The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine. J. Infect. Dis. 168:1356-60
249. Webster CB, Chen D, Horgan M, Olivo PD. 1995. The varicella-zoster virus origin-binding protein can substitute for the herpes simplex virus origin-binding protein in a transient origin-dependent DNA replication assay in insect cells. Virology 206:655-60
250. Weibel RE, Kuter BJ, Neff BJ, Rothenberger CA, Fitzgerald AJ, et al. 1985. Live Oka/Merck varicella vaccine in healthy children: further clinical and laboratory assessment. J. Am. Med. Assoc. 254:2435-39
251. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, et al. 1984. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N. Engl. J. Med. 310:1409-15
252. White CJ. 1992. Varicella vaccine reflux. Pediatrics 89:354
253. White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, et al. 1991. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 87:604-10
254. Whitley R. 1992. Therapeutic approaches to varicella-zoster virus infections. J. Infect. Dis. 166:551-557
255. Wilson A, Sharp M, Koropchak C, Ting S, Arvin A. 1992. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J. Infect. Dis. 165:119-26
256. Wilson G, Talkington D, Gruber W, Edwards K, Dermody T. 1995. Group A streptococcal necrotizing fasciitis following varicella in children: case reports and review. Clin. Infect. Dis. 20:1333-38
257. Wood MF, Johnson RW, McKendrick MW, Taylor J, Mandal B, Crooks J. 1994. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N. Engl. J. Med. 330:896-900
258. Yao Z, Grose C. 1994. Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex). J. Virol. 68:4204-11
259. Zaia J, Levin M, Preblud S, Leszcynski J, Wright G, et al. 1983. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J. Infect. Dis. 147:737-43
260. Zamora I, Simon JM, Da Silva ME, Piqueras AI. 1994. Attenuated varicella vaccine in children with renal transplants. Pediatr. Nephrol. 8:190-92
261. Zhang Y, Cosyns M, Levin MJ, Hayward AR. 1994. Cytokine production in varicella zoster virus stimulated limiting dilution lympohocyte cultures. Clin. Exp. Immunol. 98:128-33
262. Zhu Z, Gershon MD, Gabel C, Sherman D, Ambron R, Gershon AA. 1995. Entry and egress of VZV: role of mannose 6-phosphate, heparan sulfate proteoglycan, and signal sequences in targeting virions and viral glycoproteins. J. Neurol. 45:S15-S17